F.D.A. Is Said to Delay Decision on Duchenne Muscular Dystrophy Drug

The news caused a sharp rise in the stock of Sarepta Therapeutics, the maker of the drug, as some investors saw a hint of approval in the development.

from NYT > Health http://ift.tt/25gKsZp
via health&fitness